Clinical trial NCT02486302: A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
Official title: A PROSPECTIVE, MULTICENTER NON-INTERVENTIONAL STUDY TO EVALUATE THE EFFICACY OF ENBREL (REGISTERED) (ETANERCEPT) OVER A PERIOD OF 12 MONTHS IN THE ROUTINE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, OR PLAQUE PSORIASIS WITH PARTICULAR FOCUS ON THE CLINICAL STATUS IMPROVEMENTS STILL OBSERVABLE AFTER 12 WEEKS OF TREATMENT
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Psoriatic Arthritis
Axial Spondyloarthritis
Plaque Psoriasis
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2015-07-01
Enrollment: 1534
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Ambulatory and Hospital care patients treated for Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriasis Arthritis or Plaque Psoriasis in Germany

Brief summary: The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis (RA), psoriatic arthritis(PsA), axial spondyloarthritis(axSpA) or plaque psoriasis (PsO). In so doing, particular attention will be paid to the proportion of those patients who only attain the desired treatment goal after 12 weeks of treatment. The primary efficacy end point for the study is the proportion of patients who attain the desired treatment goal after 12 and 24 weeks,


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of RA, axSpA, PsA or PsO
* No prior treatment with etanercept and eligibility for treatment with etanercept according to the summary of product characteristics.

Exclusion Criteria:

* The contraindications, special warnings, and precautions according to the summary of product characteristics for etanercept shall apply.
* The additional documentation of the patient in another post-marketing study with etanercept is not permitted.

Primary outcomes:
measure: Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12
timeFrame: Week 12
measure: Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24
timeFrame: Week 24
measure: Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12 and Maintained Till 52 Weeks
timeFrame: Week 12 up to Week 52
measure: Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24 and Maintained Till 52 Weeks
timeFrame: Week 24 up to Week 52
measure: Number of Participants With PsO Who Achieved 75% Improvement From Baseline in Psoriasis Area & Severity Index(PASI75) Score or Physician's Global Assessment(PGA) of Clear or Almost Clear And Dermatology Life Quality Index(DLQI) Total Score of 0 or 1
timeFrame: Week 12
measure: Number of Participants With Axial Spondyloarthritis (axSpA) Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 12
timeFrame: Week 12
measure: Number of Participants With Psoriatic Arthritis (PsA) Who Achieved Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 12
timeFrame: Week 12
measure: Number of Participants With Plaque Psoriasis (PsO) Who Achieved 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score or a Physician's Global Assessment (PGA) of "Clear" or "Almost Clear" and DLQI Total Score of 0 or 1 at Week 24
timeFrame: Week 24
measure: Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 24
timeFrame: Week 24
measure: Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 24
timeFrame: Week 24
Secondary outcomes:
measure: Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Treated Set (TS)
timeFrame: Baseline up to Weeks 12, 24, 36, 52
measure: Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set
timeFrame: Baseline up to Weeks 12, 24, 36, 52
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to Weeks 12, 24, 36 and 52: Treated Set
timeFrame: Baseline up to Weeks 12, 24, 36, 52
measure: Number of Participants With Treatment Emergent Adverse Events up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set
timeFrame: Baseline up to Weeks 12, 24, 36, 52
measure: Number of Participants Achieving 28 Joint Disease Activity Score (DAS28) Remission at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Patient Global Assessment of Disease Activity (PtGA) Scores at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Mean Visual Analogue Scale (VAS) Fatigue Scores at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Mean Visual Analogue Scale (VAS) Pain Scores at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Physician Global Assessment (PGA) of Disease Activity Scores at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Patient Health Quessionare-2 (PHQ-2) Scores at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52
timeFrame: Weeks 12, 24, 36, 52
measure: Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52
timeFrame: Weeks 12, 24, 36, 52
measure: Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52
timeFrame: Weeks 12, 24, 36, 52
measure: Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52
timeFrame: Weeks 12, 24, 36, 52
measure: Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52
timeFrame: Weeks 12, 24, 36, 52
measure: Psoriatic Arthritis(PsA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52
timeFrame: Weeks 12, 24, 36, 52
measure: Ankylosing Spondylitis(axSpA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52
timeFrame: Weeks 12, 24, 36, 52
measure: Percentage of Participants Who Discontinued Treatment Due to Lack of Efficacy or Adverse Events
timeFrame: Baseline up to Week 52
measure: Number of Participants Who Switched to Other Therapy After Treatment Discontinuation
timeFrame: Baseline up to Week 52
measure: Hannover Functional Questionnaire (FFbH) Functional Capacity Score of Participants With Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriasis Arthritis (PsA) at Weeks 12, 24, 36, 52
timeFrame: Weeks 12, 24, 36, 52
measure: Clinical Disease Activity Index (CDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Simplified Disease Activity Index (SDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Number of Affected Enthesis in Participants With Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis(PsA) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Occiput-to-wall Distance of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Mean Percentage of Total Body Surface Area (BSA) for Participants With Plaque Psoriasis (PsO) and Psoriasis Arthritis (PsA) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Mean of Total Number of Affected Fingers or Toes by Dactylitis in Participants With Psoriatic Arthritis (PsA) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52
timeFrame: Baseline, Weeks 12, 24, 36, 52
measure: Median Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response in Participants With Plaque Psoriasis (PsO)
timeFrame: Baseline up to Week 24
measure: Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)
timeFrame: Weeks 12, 24, 36, 52
measure: Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)
timeFrame: Weeks 12, 24, 36, 52
measure: Dermatology Life Quality Index (DLQI) Total Score for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Patient Assessment of Pruritus for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
Other outcomes:
measure: Erythrocyte Sedimentation Rate (ESR) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: C-Reactive Protein (CRP) Levels at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Number of Participants With Rheumatoid Factor (RF) at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies at Weeks 12, 24, 36 and 52
timeFrame: Weeks 12, 24, 36, 52
measure: Number of Participants With Positive Human Leukocyte Antigen B27(HLA-B27) at Baseline for Participants With Axial Spondyloarthritis(axSpA)
timeFrame: Baseline
measure: Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than < 1.3 at Weeks 36 and 52
timeFrame: Weeks 36, 52
measure: Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than < 2.6 or Meet Minimal Disease Activity (MDA) Criteria at Weeks 36 and 52
timeFrame: Weeks 36, 52
measure: Number of Participants With Plaque Psoriasis (PsO) Achieving PASI75 Score or a PGA of "Clear" or "Almost Clear" And DLQI Total Score of 0 or 1 at Weeks 36 and 52
timeFrame: Weeks 36, 52
measure: Number of Participants With Rheumatoid Arthritis (RA) Achieving 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Weeks 36 and 52
timeFrame: Weeks 36, 52
Locations:
city: Dresden
country: Germany
facility: Rheumatologisches MVZ Dresden GmbH im Gesundheitszentrum Dresden - Klotzsche (GZDK)
state: Sachsen
city: Aachen
country: Germany
facility: private practise Hemmerich
city: Aachen
country: Germany
facility: private practise Kurthen
city: Alsfeld
country: Germany
facility: Gesundheits- und Pflegezentrum Alsfeld gGmbH
city: Altenburg
country: Germany
facility: private practise Kupka
city: Altenholz
country: Germany
facility: Private Practise Boehm
city: Amberg
country: Germany
facility: Private Practise Marycz
city: Bad Bramstedt
country: Germany
facility: Klinikum Bad Bramstedt
city: Bad Bramstedt
country: Germany
facility: private practise Gause
city: Bad Homburg
country: Germany
facility: private practise Messis
city: Bad Kreuznach
country: Germany
facility: ACURA Rheumazentrum Bad Kreuznach
city: Bad Kreuznach
country: Germany
facility: private practise Hesse
city: Bamberg
country: Germany
facility: private practise Manger
city: Bautzen
country: Germany
facility: private practise Balzer
city: Bautzen
country: Germany
facility: private practise Winkler
city: Bayreuth
country: Germany
facility: private practise Ochs
city: Bayreuth
country: Germany
facility: private practise Schmitt-Haendle
city: Berlin
country: Germany
facility: Charité Berlin Rheumatologie und Klinische Immunologie
city: Berlin
country: Germany
facility: Med. Versorgungszentrum Ambulantes Gesundheitszentrum Charite Campus Mitte
city: Berlin
country: Germany
facility: private practise Hasert
city: Berlin
country: Germany
facility: Praxis Roßbacher
city: Berlin
country: Germany
facility: private practise Bozorg
city: Berlin
country: Germany
facility: private practise Brandt-Jürgens
city: Berlin
country: Germany
facility: private practise Herzberg
city: Berlin
country: Germany
facility: private practise Remstedt
city: Berlin
country: Germany
facility: private practise Seifert
city: Berlin
country: Germany
facility: private practise Zinke
city: Berlin
country: Germany
facility: private practise Kors
city: Berlin
country: Germany
facility: Rheumaklinik Berlin-Buch
city: Berlin
country: Germany
facility: private practise Miehe
city: Berlin
country: Germany
facility: private practise Schnorfeil
city: Bogen
country: Germany
facility: private practise Koelnberger
city: Borna
country: Germany
facility: private practise Barth
city: Braunschweig
country: Germany
facility: private practise Eisterhues
city: Braunschweig
country: Germany
facility: Private Practise Ramaker-Brunke
city: Bremen
country: Germany
facility: private practise Mall
city: Bremen
country: Germany
facility: private practise Schwichtenberg
city: Bruchhausen-Vilsen
country: Germany
facility: Private Practise Wagener
city: Burghausen
country: Germany
facility: private practise Feuchtenberger
city: Bückeburg
country: Germany
facility: private practise Budde
city: Chemnitz
country: Germany
facility: Mvz Agliomed
city: Chemnitz
country: Germany
facility: private practise Schneider
city: Cottbus
country: Germany
facility: private practise Geißler
city: Deggendorf
country: Germany
facility: private practise Kirrstetter
city: Demmin
country: Germany
facility: Kreiskrankenhaus Demmin GmbH
city: Dessau
country: Germany
facility: private practise Heidlas
city: Dortmund
country: Germany
facility: private practise Bebnowski
city: Dresden
country: Germany
facility: private practise Gerlach
city: Dresden
country: Germany
facility: private practise Lüthke
city: Dresden
country: Germany
facility: private practise Fischer
city: Dresden
country: Germany
facility: private practise Oppers
city: Dresden
country: Germany
facility: private practise Roch
city: Duisburg
country: Germany
facility: private practise Fendler
city: Duisburg
country: Germany
facility: private practise Riesopp
city: Düsseldorf
country: Germany
facility: private practise Strothmeyer
city: Ebensfeld
country: Germany
facility: Bezirksklinikum Obermain
city: Eberswalde
country: Germany
facility: private practise Berendt
city: Eberswalde
country: Germany
facility: private practise Pech
city: Elmshorn
country: Germany
facility: Asklepios MVZ Nord SH GmbH, c/o AK St. Georg
city: Elsterwerda
country: Germany
facility: Elbe Elster MVZ GmbH
city: Erfurt
country: Germany
facility: MVZ Kaestner + Kaestner GbR
city: Erfurt
country: Germany
facility: private practise Koch
city: Essen
country: Germany
facility: Universitaetsklinikum Essen, Klinik fuer Dermatologie
city: Falkensee
country: Germany
facility: private practise Freitag
city: Frankenberg
country: Germany
facility: private practise Häckel
city: Frankfurt/Main
country: Germany
facility: Klinikum der J.W. Goethe-Universität, Klinik für Dermatologie, Klinische Forschung
city: Frankfurt
country: Germany
facility: private practise Fritzsch
city: Fraureuth
country: Germany
facility: private practise Höhne
city: Freiberg
country: Germany
facility: private practise Müller
city: Fulda
country: Germany
facility: private practise Behringer
city: Geilenkirchen
country: Germany
facility: private practise Bussmann
city: Geislingen A.d. Steige
country: Germany
facility: private practise Zeh
city: Germering
country: Germany
facility: Private Practice Abahji
city: Giessen
country: Germany
facility: Private Practise
city: Gladbeck
country: Germany
facility: Praxis Dres. Dr.Brinkmann, Schult, Samimi-Fard
city: Haldensleben
country: Germany
facility: private practise Kühne
city: Halle
country: Germany
facility: private practise Liebhaber
city: Hamburg
country: Germany
facility: MVZ Rheumatologie und Autoimmunmedizin GmbH
city: Hamburg
country: Germany
facility: MVZ Nord GmbH
city: Hamburg
country: Germany
facility: Katholisches Marienkrankenhaus Geriatrische Klinik
city: Hamburg
country: Germany
facility: Private Practise Höhle
city: Hamburg
country: Germany
facility: private practise Dahmen
city: Hamburg
country: Germany
facility: private practise Weinhardt
city: Hamburg
country: Germany
facility: private practise Aries
city: Hamm
country: Germany
facility: Praxis Praxis Dr. Szabo & Kollegen
city: Hannover
country: Germany
facility: Private Practise Stille
city: Hannover
country: Germany
facility: private practise Stein
city: Heidelberg
country: Germany
facility: private practise Heilig
city: Heidelberg
country: Germany
facility: private practise Lassak-Siedl
city: Heidelberg
country: Germany
facility: Universitätsklinikum Heidelberg
city: Heilbad Heiligenstadt
country: Germany
facility: private Practise Pawlak
city: Heilbad Heiligenstadt
country: Germany
facility: private practise Schleußner
city: Herrsching
country: Germany
facility: private practise Thies
city: Hofheim
country: Germany
facility: private practise Meier
city: Hohen Neuendorf
country: Germany
facility: private practise Wernicke
city: Holzkirchen
country: Germany
facility: Private Practice Streibl
city: Hoyerswerda
country: Germany
facility: private practise Kapelle
city: Jena
country: Germany
facility: Uniklinik Jena
city: Jülich
country: Germany
facility: Private Practise Kremers
city: Kahla
country: Germany
facility: private practise Bräunig
city: Kamenz
country: Germany
facility: Praxis Mauer
city: Karlstadt
country: Germany
facility: Private Practise Turin
city: Kiel
country: Germany
facility: private practise Schwab
city: Koeln
country: Germany
facility: Office of Parysa Alborz, MD
city: Kronach
country: Germany
facility: private practise Straub
city: Köln
country: Germany
facility: private practise Wilden
city: Königs Wusterhausen
country: Germany
facility: private practise Merkel
city: Langenau
country: Germany
facility: Kreiskrankenhaus Langenau
city: Leipzig
country: Germany
facility: Boche-Hamann-Teich
city: Leipzig
country: Germany
facility: private practise Schwarze
city: Leipzig
country: Germany
facility: private practise Zeiger
city: Leipzig
country: Germany
facility: private practise Wiemers
city: Lichtenstein
country: Germany
facility: private practise Weiß
city: Ludwigslust
country: Germany
facility: private practise Holst
city: Luebeck
country: Germany
facility: Private Practise Legler
city: Magdeburg
country: Germany
facility: private practise Kudela
city: Magdeburg
country: Germany
facility: private practise Raschke
city: Magdeburg
country: Germany
facility: private practise Sieburg
city: Magdeburg
country: Germany
facility: private practise Weimann
city: Mainz
country: Germany
facility: Hautklinik der Universitätsmedizin Mainz KöR,Clinical Research Center
city: Malchow
country: Germany
facility: private practise Zimmermann
city: Mansfeld OT Großörner
country: Germany
facility: Praxis Roßbach
city: Marktredwitz
country: Germany
facility: private practise Harmuth
city: Marl
country: Germany
facility: Private Practise Bödekker
city: Mittelherwigsdorf
country: Germany
facility: private practise Reck
city: Monchengladbach
country: Germany
facility: private practise Vollmer
city: Munchen
country: Germany
facility: Stadt Klinikum Muenchen
city: München
country: Germany
facility: private practise Krüger
city: Münster
country: Germany
facility: private practise Raub
city: Naunhof
country: Germany
facility: private practise Berger
city: Neubrandenburg
country: Germany
facility: private practise Klopsch
city: Neumünster
country: Germany
facility: Rheumazentrum SH Mitte GbR
city: Neustadt-Glewe
country: Germany
facility: private practise Scholz
city: Neuwied
country: Germany
facility: private practise Kloos
city: Nienburg
country: Germany
facility: Private Practise Hein
city: Nürnberg
country: Germany
facility: Private Practise Vogel
city: Offenburg
country: Germany
facility: private practise Albert
city: Oldenburg
country: Germany
facility: private practise Voglau
city: Pirna
country: Germany
facility: private practise Gräßler
city: Planegg
country: Germany
facility: private practise Welcker
city: Plauen
country: Germany
facility: private practise Baumann
city: Potsdam
country: Germany
facility: Private Practise Petersen
city: Potsdam
country: Germany
facility: Rheumahaus Potsdam GbR
city: Püttlingen
country: Germany
facility: Knappschaftskrankenhaus Püttlingen
city: Ratingen
country: Germany
facility: private practise Wassenberg
city: Ratzeburg
country: Germany
facility: private practise Schwokowski
city: Regensburg
country: Germany
facility: private practise Rumpel
city: Reken
country: Germany
facility: private practise Schumann
city: Rendburg
country: Germany
facility: Private Practise Walter
city: Reutlingen
country: Germany
facility: Private Practise Kotterik
city: Rostock
country: Germany
facility: Private Practise Hoene
city: Rostock
country: Germany
facility: private practise Richter
city: Rostock
country: Germany
facility: private practise Lankow
city: Saarbrücken
country: Germany
facility: private practise Biewer
city: Schwerin
country: Germany
facility: Private Practise Mobius
city: Schwerin
country: Germany
facility: private practise Möbius
city: Schwerin
country: Germany
facility: private practise Ständer
city: Seesen
country: Germany
facility: private practise Melzer
city: Selters/Ww
country: Germany
facility: Company for Medical Study&Service Selters
city: Stadthagen
country: Germany
facility: Private Practise Hoese
city: Straubing
country: Germany
facility: private practise Steinborn
city: Stuttgart
country: Germany
facility: private practise Engel
city: Stuttgart
country: Germany
facility: ZIRS - Zentrum für Interdisziplinäre Rheumatologie Stuttgart
city: Suhl
country: Germany
facility: Private Practice Fahr
city: Torgelow
country: Germany
facility: private practise Pyra
city: Treuenbrietzen
country: Germany
facility: MVZ der Johanniter
city: Tübingen
country: Germany
facility: Praxis Dr. Haas
city: Tübingen
country: Germany
facility: Private Practice Jacki
city: Tübingen
country: Germany
facility: Universitätsklinikum Tübingen
city: Ulm / Donau
country: Germany
facility: Berufsausübungsgemeinschaft Dr. med Petra Roll und Dr. Margarete Kratzsch
city: Ulm / Donau
country: Germany
facility: private practise Rinaldi
city: Unna
country: Germany
facility: Praxis Dres. Winkler-Gyulay, Moeller
city: Wesel
country: Germany
facility: private practise Otte
city: Wissen/ Luhe
country: Germany
facility: private practise Schuart
city: Wittstock
country: Germany
facility: private practise Metz
city: Wunstorf
country: Germany
facility: private practise Senger
city: Wuppertal
country: Germany
facility: Klinikverbund St. Antonius und St. Josef GmbH, Krankenhaus St. Josef
city: Zeven
country: Germany
facility: Private Practise Sprekeler
city: Zwickau
country: Germany
facility: private practise Fricke-Wagner
city: Zwiesel
country: Germany
facility: private practise Alliger
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Feist E, Baraliakos X, Behrens F, Thaci D, Klopsch T, Plenske A, Blindzellner LK, Klaus P, Meng T, Loschmann PA. Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes. Rheumatol Ther. 2022 Apr;9(2):621-635. doi: 10.1007/s40744-021-00418-5. Epub 2022 Feb 3.